SCHEMBL596333

SCHEMBL596333

Brc1ccc2c(c1)NCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.48
ASIC3 Q9UHC3 1/20 0.48
PARP10 Q53GL7 2/20 0.44
PARP1 P09874 1/20 0.44
CMA1 P23946 1/20 0.43
AHR P35869 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
PARP11 Q9NR21 1/20 0.41
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29417773 1.00 PNMT (0.48) PNMTASIC3PARP10PARP1CMA1
Hydrochloric Acid SCHEMBL16397223 0.98 PNMT (0.47) PNMTASIC3PARP10PARP1CMA1
SCHEMBL1246501 0.94 PNMT (0.47) PNMTASIC3PARP10PARP1CMA1
Hydrochloric Acid SCHEMBL31437001 0.92 PNMT (0.46) PNMTASIC3PARP10PARP1CMA1
SCHEMBL29414378 0.88 PNMT (0.57) PNMTASIC3PARP10PARP1CMA1
SCHEMBL1612916 0.88 PNMT (0.57) PNMTASIC3PARP10PARP1CMA1
Hydrochloric Acid SCHEMBL595700 0.86 PNMT (0.55) PNMTASIC3PARP10PARP1CMA1
SCHEMBL1556861 0.84 MAPT (0.54) PNMTASIC3PARP10PARP1HRH3
Hydrochloric Acid SCHEMBL18549588 0.82 MAPT (0.53) PNMTASIC3PARP10PARP1HRH3
SCHEMBL4556315 0.80 MAPT (0.47) PNMTASIC3PARP10PARP1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117229275-B Novel 2-acetamido thiazole compound and preparation method and application thereof 北京中医药大学 2024-06-18 CN claimed
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 AJAX THERAPEUTICS INC (US) 2026-03-19 US disclosed
EP-4676476-A1 INHIBITORS OF TDP-43 AND TAU AGGREGATION Aquinnah Pharmaceuticals, Inc. (US) 2026-01-14 EP disclosed
EP-4596544-A1 EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Miracure Biotechnology Limited (CN) 2025-08-06 EP disclosed
EP-4585596-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Yingli Pharmaceutical Co., Ltd (CN) 2025-07-16 EP disclosed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
WO-2025108411-A1 EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京沐华生物科技有限责任公司 2025-05-30 WO disclosed
US-20250115628-A1 FLUORINATED FLUOROPHORES HOWARD HUGHES MEDICAL INSTITUTE 2025-04-10 US disclosed
US-12253526-B2 Fluorescent dye and use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-03-18 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
EP-0994862-A2 SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM PLC (GB) 2000-04-26 EP disclosed
WO-1999002502-A2 SULPHONAMIDE DERIVATIVES BEING 5-HT6 RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM PLC (GB) 1999-01-21 WO disclosed
US-5736534-A HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA PFIZER INC. (US) 1998-04-07 US disclosed
CN-1141633-A 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents PFIZER (US) 1997-01-29 CN disclosed
EP-0746554-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1996-12-11 EP disclosed
WO-1995023141-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1995-08-31 WO disclosed
EP-0173208-A1 Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-03-05 EP disclosed
US-4210757-A Novel naphthoylene-perinones disperse dyestuffs CIBA-GEIGY CORPORATION (US) 1980-07-01 US disclosed
US-4067889-A 2-CYANO-3-AMINO-BENZANTHRONES AS PRECURSORS CIBA-GEIGY CORPORATION (US) 1978-01-10 US disclosed
US-3970675-A ANTHRONE-AMIDINE CIBA-GEIGY CORPORATION (US) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PNMT 1059/4885ASIC3 4413/4885PARP10 1324/4885
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 JAK2, JAK1, JAK3 PNMT 1433/4885ASIC3 2820/4885PARP10 2555/4885
US-20250115628-A1 FLUORINATED FLUOROPHORES PFAS, FLI1, ARFGEF1 PNMT 491/4885ASIC3 2468/4885PARP10 735/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PNMT 1059/4885ASIC3 4413/4885PARP10 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.